Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Betahistine in Ménière's disease

T J Wilmot, G N Menon

    The Journal of Laryngology and Otology
    |September 1, 1976
    PubMed
    Summary

    Betahistine hydrochloride significantly improved vertigo, tinnitus, and ear fullness in Ménière

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hypoplastic Anaemia-An Unusual Complication of Chlordiazepoxide Hydrochloride Therapy.

    Postgraduate medical journal·2011
    Same author

    Whither vestibular tests?

    Journal of the Royal Society of Medicine·2010
    Same author

    Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study.

    The Journal of rheumatology·1995
    Same author

    High-performance liquid chromatographic assay for thyrotropin releasing hormone and benzyl alcohol in injectable formulation.

    Pharmaceutical research·1987
    Same author

    CNS pharmacology and clinical therapeutic effects of oxiracetam.

    Clinical neuropharmacology·1986
    Same author

    A double-blind clinical trial of hydroxyethylrutosides in Menière's disease.

    The Journal of laryngology and otology·1984

    Area of Science:

    • Otolaryngology
    • Neurology
    • Pharmacology

    Background:

    • Ménière's disease is a chronic inner ear disorder characterized by vertigo, tinnitus, and hearing loss.
    • Current treatments offer limited efficacy and can have side effects.

    Purpose of the Study:

    • To evaluate the efficacy of betahistine hydrochloride in managing Ménière's disease symptoms.
    • To assess the safety profile of betahistine hydrochloride.

    Main Methods:

    • Two double-blind, placebo-controlled, cross-over studies.
    • Inclusion of 24 Ménière's disease patients with confirmed diagnosis.
    • Treatment duration of 8 or 12 weeks with betahistine hydrochloride (16 mg t.i.d.) or placebo.

    Main Results:

    • Betahistine hydrochloride showed statistically significant improvements in vertigo (p=0.025), tinnitus (p=0.010), and ear fullness (p=0.036) compared to placebo.
    • Objective audiometric measurements demonstrated a highly significant improvement in deafness (p<0.001) with betahistine.
    • No significant differences were observed in vestibular testing outcomes.
    • No adverse events were reported with betahistine hydrochloride treatment.

    Conclusions:

    • Betahistine hydrochloride is an effective treatment for Ménière's disease, significantly alleviating key symptoms and improving hearing.
    • The drug is well-tolerated with a favorable safety profile.

    Related Experiment Videos